1. Reynolds GJ, Annis KA, de Villiers WJ. Review article: multiple myeloma and inflammatory bowel disease. Dig Dis Sci. 2007; 52:2022–2028. PMID:
17420948.
Article
2. Carter A, Tatarsky I. The physiopathological significance of benign monoclonal gammopathy: a study of 64 cases. Br J Haematol. 1980; 46:565–574. PMID:
7437335.
Article
3. Greipp PR, Lust JA. Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. Stem Cells. 1995; 13(Suppl 2):10–21. PMID:
8520496.
4. Bouhnik Y, Lémann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996; 347:215–219. PMID:
8551879.
Article
5. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000; 47:514–519. PMID:
10986211.
Article
6. Gazitt Y, Shaughnessy P, Montgomery W. Apoptosis-induced by TRAIL and TNF-alpha in human multiple myeloma cells is not blocked by BCL-2. Cytokine. 1999; 11:1010–1019. PMID:
10623426.
Article
7. Robertson EJ, Al-Kaisi NK, Vareska GJ, Ponsky JL. Plasmacytoma of the ileum complicating Crohn’s disease: report of a case and review of the literature. Surgery. 1986; 100:916–923. PMID:
3775661.
8. Freeman HJ. Tabulation of myeloid, lymphoid and intestinal malignancies in Crohn's disease. Can J Gastroenterol. 2002; 16:779–784. PMID:
12464971.
Article
9. Nakajima H, Munakata A, Yoshida Y. Extraintestinal cancers in Crohn's disease. Digestion. 1990; 47:1–7.
Article
10. Ligato S, El-Naggar A, Cleary KR, Manning J. Extramedullary plasmacytoma mimicking primary colonic carcinoma in a patient with Crohn's disease: case report and literature review. Arch Pathol Lab Med. 1996; 120:279–282. PMID:
8629905.
11. Minami A, Iwai A, Watanabe Y, et al. Two cases of inflammatory bowel disease with multiple myeloma. J Gastroenterol. 1999; 34:629–633. PMID:
10535494.
Article
12. Liu H, Moreb JS. Association of multiple myeloma and inflammatory bowel diseases. Dig Dis Sci. 2008; 53:863–864. PMID:
17717742.
Article
13. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15:e538–e548. PMID:
25439696.
14. Brandtzaeg P, Halstensen TS, Kett K, et al. Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology. 1989; 97:1562–1584. PMID:
2684725.
Article
15. Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect Prev. 1996; 20:52–56. PMID:
8907203.
16. Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res. 2003; 27:375–380. PMID:
12620287.
Article
17. Bladé J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma. 1998; 30:493–501. PMID:
9711912.
Article
18. Mielke F, Schweigert M. Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma. Nat Clin Pract Rheumatol. 2008; 4:218–221. PMID:
18301411.
Article
19. Shareef MS, Munro LR, Owen RG, Highet AS. Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum. Clin Exp Dermatol. 2012; 37:146–148. PMID:
22103549.
Article